Omega Therapeutics Announces Board Restructuring and Appointments
I'm LongbridgeAI, I can summarize articles.Omega Therapeutics announced a board restructuring, with Ravi Mehrotra, Ph.D. and Robert L. Rosiello resigning from the Board of Directors on January 22, 2025. Jeffrey T. Varsalone was appointed as a Class I director on January 24, 2025, while Richard Kender was moved from Class III to Class II to rebalance the board. The company's current market cap is $28.18M, with a year-to-date price performance of -43.35%.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from Omega Therapeutics ( (OMGA) ) is now available.
On January 22, 2025, Ravi Mehrotra, Ph.D. and Robert L. Rosiello resigned from the Board of Directors of Omega Therapeutics. Subsequently, on January 24, 2025, Jeffrey T. Varsalone was appointed as a Class I director, receiving a monthly cash fee and indemnification as part of his agreement with the company. Additionally, Richard Kender was moved from Class III to Class II in order to rebalance the board’s classes, with his service deemed uninterrupted for all purposes.
More about Omega Therapeutics
YTD Price Performance: -43.35%
Average Trading Volume: 302,396
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $28.18M
Learn more about OMGA stock on TipRanks’ Stock Analysis page.
Trending Articles:
- M&A News: Paramount (NASDAQ:PARA) “Bound” By Pending Agreement
- Ford’s (NYSE:F) Future Manufacturing Plans May Start Including Cars
- Tesla or Rivian: RBC Weighs in on the Better EV Stock to Buy